GB0702871D0 - Improved compositions and combinations 1 - Google Patents

Improved compositions and combinations 1

Info

Publication number
GB0702871D0
GB0702871D0 GBGB0702871.5A GB0702871A GB0702871D0 GB 0702871 D0 GB0702871 D0 GB 0702871D0 GB 0702871 A GB0702871 A GB 0702871A GB 0702871 D0 GB0702871 D0 GB 0702871D0
Authority
GB
United Kingdom
Prior art keywords
combinations
improved compositions
compositions
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0702871.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TCP Innovations Ltd
Original Assignee
TCP Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TCP Innovations Ltd filed Critical TCP Innovations Ltd
Priority to GBGB0702871.5A priority Critical patent/GB0702871D0/en
Publication of GB0702871D0 publication Critical patent/GB0702871D0/en
Priority to PCT/GB2008/000451 priority patent/WO2008099144A2/en
Priority to CN200880009702A priority patent/CN101668543A/zh
Priority to EP08709352A priority patent/EP2121020A2/en
Priority to JP2009549466A priority patent/JP2010518154A/ja
Priority to CA002678127A priority patent/CA2678127A1/en
Priority to US12/527,337 priority patent/US20100099642A1/en
Priority to RU2009134039/15A priority patent/RU2009134039A/ru
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0702871.5A 2007-02-14 2007-02-14 Improved compositions and combinations 1 Ceased GB0702871D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0702871.5A GB0702871D0 (en) 2007-02-14 2007-02-14 Improved compositions and combinations 1
PCT/GB2008/000451 WO2008099144A2 (en) 2007-02-14 2008-02-07 Tgf-beta stimulant and further agent to reduce side effects
CN200880009702A CN101668543A (zh) 2007-02-14 2008-02-07 TGF-β激动剂和减轻副作用的其他药剂
EP08709352A EP2121020A2 (en) 2007-02-14 2008-02-07 Tgf-beta stimulant and further agent to reduce side effects
JP2009549466A JP2010518154A (ja) 2007-02-14 2008-02-07 副作用を減少させる、ｔｇｆ−ベータ刺激因子及び追加の剤
CA002678127A CA2678127A1 (en) 2007-02-14 2008-02-07 Tgf-beta stimulant and further agent to reduce side effects
US12/527,337 US20100099642A1 (en) 2007-02-14 2008-02-07 Tgf-beta stimulant and further agent to reduce side effects
RU2009134039/15A RU2009134039A (ru) 2007-02-14 2008-02-07 Стимуляторы tgf-бета и другие агенты для уменьшения побочных эффектов

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0702871.5A GB0702871D0 (en) 2007-02-14 2007-02-14 Improved compositions and combinations 1

Publications (1)

Publication Number Publication Date
GB0702871D0 true GB0702871D0 (en) 2007-03-28

Family

ID=37908631

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0702871.5A Ceased GB0702871D0 (en) 2007-02-14 2007-02-14 Improved compositions and combinations 1

Country Status (8)

Country Link
US (1) US20100099642A1 (enExample)
EP (1) EP2121020A2 (enExample)
JP (1) JP2010518154A (enExample)
CN (1) CN101668543A (enExample)
CA (1) CA2678127A1 (enExample)
GB (1) GB0702871D0 (enExample)
RU (1) RU2009134039A (enExample)
WO (1) WO2008099144A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
GB2475907A (en) * 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
US20110136858A1 (en) * 2009-12-04 2011-06-09 Grainger David J Preferred Combination Therapy
WO2015103355A1 (en) 2014-01-01 2015-07-09 Medivation Technologies, Inc. Compounds and methods of use
CN104211778A (zh) * 2014-09-28 2014-12-17 苏州普罗达生物科技有限公司 一种转化生长因子β1激动剂多肽及其制备方法、应用
CN104311631A (zh) * 2014-09-28 2015-01-28 苏州普罗达生物科技有限公司 转化生长因子β1激动剂多肽及其制备方法、应用
WO2020097317A1 (en) * 2018-11-07 2020-05-14 Health Research, Inc. Exploiting estrogen receptor beta and tp53 interaction as a new therapeutic strategy for cancer
CN116152157A (zh) * 2022-11-28 2023-05-23 苏州大学 基于肿瘤组织灌注影像学特征的生物标志物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251920B1 (en) * 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies

Also Published As

Publication number Publication date
WO2008099144A3 (en) 2008-12-04
EP2121020A2 (en) 2009-11-25
CN101668543A (zh) 2010-03-10
CA2678127A1 (en) 2008-08-21
JP2010518154A (ja) 2010-05-27
WO2008099144A2 (en) 2008-08-21
US20100099642A1 (en) 2010-04-22
RU2009134039A (ru) 2011-03-20

Similar Documents

Publication Publication Date Title
ZA201001300B (en) Antigen-asjuvant compositions and methods
EP2162004A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
IL202826A0 (en) New compounds and their uses 708
DK2139466T3 (en) Magnesium Compositions and Uses Thereof
EP2219554A4 (en) PROGESTER-CONTAINING COMPOSITIONS AND DEVICES
ZA201008887B (en) Oral compositions and uses thereof
GB2455539B (en) Anti-inflammatory compositions and combinations
ZA201007920B (en) Oral compositions and uses thereof
EP2046936A4 (en) BIOCIDAL COMPOSITIONS AND METHODS
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
GB0721291D0 (en) Methods and compositions
GB0602325D0 (en) Virucidal compositions and uses
GB0717376D0 (en) Composition and manufacture thereof
GB0702871D0 (en) Improved compositions and combinations 1
IL202496A0 (en) Compounds and uses thereof 849
IL201015A0 (en) New compounds and their uses 707
GB0719526D0 (en) Compositions and methods
GB0809912D0 (en) Novel compositions and uses thereof
GB0622399D0 (en) Novel compositions and uses thereof
GB0715428D0 (en) Compositions and uses thereof
GB0617171D0 (en) Novel compositions and methods
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0725264D0 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)